# OnCo record vivek-subbiah (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/vivek-subbiah/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "vivek-subbiah" ;
  schema:name "Vivek Subbiah"@en ;
  schema:description "Early-phase trialist who led the study showing dabrafenib and trametinib work in BRAF-mutant anaplastic thyroid cancer, the first approved treatment for that disease, and many of the RET inhibitor trials."@en ;
  schema:url <https://onco.cc/people/vivek-subbiah/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  onco:tag "thyroid", "targeted-therapy", "early-phase", "trialist" ;
  schema:jobTitle "Medical oncologist and Chief of Early-Phase Drug Development, Sarah Cannon Research Institute" ;
  onco:cancers <https://onco.cc/cancers/anaplastic-thyroid-cancer/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/medullary-thyroid-cancer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-subbiah-dabrafenib-trametinib-atc-jco-2018/> .